{
    "relation": [
        [
            "",
            "MK-0518 400 mg b.i.d.",
            "Efavirenz 600 mg q.h.s."
        ],
        [
            "Description",
            "MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA\u00ae (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA\u00ae is recommended in all participants with creatinine clearance 30-49 mL/min.",
            "Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA\u00ae with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA\u00ae is recommended in all participants with creatinine clearance 30-49 mL/min."
        ]
    ],
    "pageTitle": "A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00369941?sect=Xl015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990611.52/warc/CC-MAIN-20150728002310-00221-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 865189199,
    "recordOffset": 865175425,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{2349=Primary therapy period: 14-Sep-2006 to 06-May-2009}",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Primary therapy period: 14-Sep-2006 to 06-May-2009 Multicenter (67) in the United States (18) and Ex-US (49) Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: MK-0518 Drug: Comparator: efavirenz Drug: Comparator: Truvada Drug: Comparator: Placebo to MK-0518 Drug: Comparator: Placebo to efavirenz Interventions: HIV Infections Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 MK-0518 400 mg b.i.d. \u00a0 \u00a0 Efavirenz 600 mg q.h.s. \u00a0 STARTED \u00a0 \u00a0 282 \u00a0 \u00a0 284 \u00a0 Treated \u00a0 \u00a0 281 \u00a0 \u00a0 282 \u00a0 COMPLETED \u00a0 \u00a0 210 \u00a0 \u00a0 184 \u00a0 NOT COMPLETED \u00a0 \u00a0 72 \u00a0 \u00a0 100 \u00a0 Never Treated \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 14 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 28 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}